C5a is a small but powerful protein fragment that triggers inflammation and recruits immune cells to sites of infection or injury. It forms when your immune system’s complement cascade, a chain reaction of proteins in the blood, splits a larger protein called C5 into two pieces. The smaller piece, C5a, acts as a chemical alarm signal. The larger piece, C5b, goes on to help form structures that punch holes in bacteria. C5a’s job is to rally the troops and amplify the body’s defensive response, but when produced in excess, it can cause serious harm.
How C5a Is Produced
C5a is generated by an enzyme called C5 convertase, a serine protease that cuts the C5 protein at a specific site. This cleavage is the last enzymatic step in the complement activation cascade, a series of protein reactions that can be triggered by antibodies binding to pathogens, by direct recognition of foreign surfaces, or by other immune signals. All three of these activation routes converge on the same step: splitting C5 into C5a and C5b.
The reaction happens both on cell surfaces and in the fluid phase of blood. Once released, C5a doesn’t stay in one place. It diffuses outward from the site where complement was activated, creating a concentration gradient that nearby immune cells can follow like a trail.
Recruiting Immune Cells to the Scene
C5a’s most important job is acting as a chemoattractant, a molecule that pulls immune cells toward a threat. Neutrophils, the most abundant white blood cells and the body’s first responders to infection, are especially sensitive to it. When neutrophils encounter C5a, they undergo a rapid physical transformation. Within about five minutes, they shift from a round, passive shape to an elongated, polarized form built for movement. This involves reorganizing their internal skeleton of actin filaments, increasing membrane flexibility, and slightly swelling in size.
The result is a cell that can squeeze through blood vessel walls and crawl toward the source of inflammation. C5a doesn’t just attract neutrophils; it also activates them, priming them to engulf bacteria, generate toxic oxygen molecules to kill pathogens, and release enzymes that break down damaged tissue. Other immune cells, including monocytes and macrophages, also respond to C5a signaling.
Triggering the Inflammatory Response
C5a was originally identified as an “anaphylatoxin,” a term coined in the early twentieth century when researchers noticed that mixing antibody complexes with fresh serum in guinea pigs produced a toxic substance capable of causing anaphylactic shock through smooth muscle contractions. C5a drives this kind of inflammatory reaction through several mechanisms at once.
It stimulates mast cells to release histamine, which dilates blood vessels and makes them leaky. This increased vascular permeability lets fluid and proteins flood into tissue, producing the swelling, redness, and warmth associated with inflammation. C5a also triggers immune cells to release pro-inflammatory signaling molecules like TNF-alpha and IL-6, which further amplify the response and recruit even more immune cells. In the liver, C5a receptor signaling activates key molecular pathways involved in both inflammation and tissue regeneration.
Two Receptors, Different Effects
C5a acts on cells by binding to two different surface receptors, called C5aR1 and C5aR2, and they don’t do the same thing. C5aR1 is the primary driver of C5a’s inflammatory effects. When C5a locks onto C5aR1, it triggers degranulation (the release of chemical weapons from immune cells), cytokine production, and oxidative burst, the rapid generation of reactive oxygen species used to kill microbes.
C5aR2 is more mysterious. It’s structurally similar to C5aR1 but isn’t coupled to the same internal signaling machinery. Research in mice lacking one receptor or the other has shown opposing effects: animals without C5aR1 had a reduced inflammatory response after bone fracture, while those without C5aR2 had an enhanced one. This suggests C5aR2 may act as a brake on C5aR1, limiting how much inflammation C5a can cause. However, under certain conditions, C5aR2 can also promote inflammation through alternative signaling routes. The balance between these two receptors helps determine whether C5a’s effects stay protective or become destructive.
When C5a Turns Harmful
In a healthy immune response, C5a production is brief and localized. Problems arise when the complement system is activated too aggressively or for too long, flooding the body with C5a.
Sepsis is the clearest example. During severe infection, complement activation goes into overdrive, producing large amounts of C5a throughout the bloodstream. Paradoxically, this excess C5a doesn’t enhance immune defense. Instead, it cripples it. Neutrophils exposed to too much C5a lose their ability to generate reactive oxygen species, engulf bacteria, and migrate toward threats. Their C5aR1 receptors become saturated and are pulled off the cell surface, leaving the cells functionally paralyzed. This state, sometimes called immunoparalysis, is associated with worse outcomes in septic patients.
In ANCA-associated vasculitis, an autoimmune condition affecting blood vessels, C5a creates a destructive feedback loop. It primes neutrophils, making them more responsive to the autoantibodies (ANCA) that drive the disease. Once activated, those neutrophils release factors that generate even more C5a, perpetuating the cycle of inflammation and tissue damage.
Normal Blood Levels
In healthy people, C5a circulates at low levels in the blood. Studies measuring peripheral blood concentrations in healthy adults report average values around 8 to 9 ng/ml. Elevated levels have been observed in various inflammatory conditions. In fibromyalgia, for instance, average C5a concentrations were roughly 12.7 ng/ml, significantly higher than in healthy controls.
Drugs That Target C5a
Because C5a drives so much inflammatory damage, it has become a target for drug development. Two main strategies exist. The first blocks the cleavage of C5 entirely, preventing both C5a and C5b from being produced. Eculizumab and ravulizumab work this way, and they are used primarily in conditions where the entire terminal complement pathway causes harm, such as certain kidney diseases and a blood disorder called paroxysmal nocturnal hemoglobinuria.
The second strategy is more selective. Avacopan (brand name Tavneos) blocks only the C5aR1 receptor, stopping C5a’s inflammatory signaling while leaving the rest of the complement system intact. This means the body can still form the membrane attack complex (from C5b) to kill bacteria, preserving some immune defense. Avacopan was approved in the United States as an add-on treatment for ANCA-associated vasculitis, where its ability to block neutrophil activation and recruitment directly addresses the disease mechanism. Its selective approach represents a shift toward more precise complement-targeted therapies that aim to quiet the harmful effects of C5a without shutting down immune functions the body still needs.